CGS 27023A. CDG 27023A.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011719:Pyrazines; D011817:Rabbits; D051381:Rats; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013449:Sulfonamides
D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; C097658:CGS 27023A; D015507:Drugs, Investigational; D006877:Hydroxamic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013449:Sulfonamides; D008666:Metalloendopeptidases